Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
This is a temporary reset, not a return to square one
Provider-determined dose and weekly cadence
Phase III clinical data from SCENESSE trials (the FDA-approved formulation of afamelanotide) demonstrated that patients with erythropoietic protoporphyria achieved clinically meaningful photoprotection after 60 days of sustained drug delivery via controlled-release implant
Thereaux J, Lesuffleur T, Pata M, et al
Early improvement typically reflects metabolic stabilization and reduced blood sugar swings
07 Use within shelf life Most stability references suggest using reconstituted multi-peptide blends within 14-28 days when refrigerated
US$ 25.64
US$ 22.97
US$ 24.98
US$ 20.86
US$ 22.80
US$ 28.73
US$ 20.79
US$ 22.64
US$ 24.68
